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There are dozens of different opioids available, and each one has a unique structure that 
allows it to produce specific responses in the body. Some of these drugs even produce responses 
that can help treat recovering addicts. Since each opioid behaves a little differently, many 
different options are available for opiate addiction treatment.  
Agonists can stop withdrawal symptoms without producing the euphoric highs. At the 
same time, agonists work to stabilize the body’s functions and return them to their pre-addiction 
levels. Methadone is a common agonist treatment that can decrease an addict’s tolerance to 
heroin or other opiates. Antagonists can block the effects if any further opiates are injected. 
Naltrexone is used to condition addicts, so they stop associating heroin with highs. 
While the various opioid structures provide a wide array of treatment options, it also 
means that each treatment has its own disadvantages. Therefore, it is supposed that the most 
effective addiction treatments combine the effects of agonists and antagonists. Buprenorphine is 
an agonist and a partial antagonist. It combines the two treatment methods to provide a more 







Heroin is one of the most common addictive drugs. It is estimated that there are 810,000 
heroin addicts in the United States each year, according to the National Institute of Health. 
However, only 20% of these addicts will receive the help that they need, and addicts who do 
enter treatment are not always guaranteed to remain heroin-free (NIH, 2013). The problem lies in 
the way that heroin addiction is treated. There are many different drugs available for treatment, 
and each one varies in its structure, properties, and effects. How do these drugs differ? Which 
one has the most success? Scientists continue to only grasp for a treatment to an addiction that 
has been haunting humanity for centuries.  
Heroin addiction started in ancient times, with an addictive painkiller called opium 
(Adams, 2014). Opium is extracted from poppy plants; drugs are then created by extracting the 
alkaloids in the opium. Morphine and codeine are both synthesized in this way (Adams, 2014). 
As people continued to discover the power of opium, they also began to realize its 
addictive properties (Adams, 2014). This initiated the pursuit to synthesize painkillers that were 
not addictive. Drugs like oxycodone and heroin are synthesized by altering the chemical 
structure of morphine, and while these drugs still possess analgesic properties, they are often 
found to be more addictive. (Adams, 2014).  
Molecules like heroin, morphine, codeine, and oxycodone enter the body through 
ingestion, injection, or absorption, but the body is also able to produce its own natural 
painkillers. These proteins, named opioids after the exogenous painkillers derived from opium, 
are coded for by genes in the body. The peptides work to block pain neurons the periaqueductal 
gray region in the brain, which lessens the body’s pain response (Pasternak, 2014). The umbrella 
term for these endogenous opioid peptides is endorphins. Endorphins can then be broken down 
into three classes: endomorphins, dynorphins, and enkephalins (Pasternak, 2014).  
Each type of endogenous endorphin and exogenous opiate interacts in the body by 
binding to a specific receptor. In this case, opioid receptors are responsible for the strong effects 
that these molecules produce in the body (Cong et al., 2015). These highly specific receptors are 
generally divided into three classes: mu opioid receptors (MORs), delta opioid receptors (DORs), 
and kappa opioid receptors (KORs), although only the MORs and KORs are associated with 
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addiction treatment. Each opioid receptor is connected to a G-protein pathway that allows them 
to produce various responses (Cong et al., 2015).  
MORs are found in the mesocorticolimbic region of the brain where they affect the 
dominergic pathway (Kudo et al., 2014). The most common endogenous ligands for mu opioid 
receptors are enkephalin and the beta-endorphins, inhibitory molecules that are linked to the 
perception of pain. Neurons in the bed nucleus of the stria terminalis (BST) produce and release 
the endogenous opioid enkephalins. The enkephalins travel to the ventral tegmental area (VTA) 
where MORs are located on the plasma membranes of neurons that produce gamma-
Aminobutyric acid (GABA). The binding of enkephalin to the MOR decreases the release of 
GABA and increases the release of dopamine, producing a high (Kudo et al., 2014).  
KORs work primarily with dynorphins and enkephalins. The ligand receptor system 
modifies emotions in response to pain (Cahill et al., 2014). KORs are the driving force behind 
the stress response and negative changes in mood that are often associated with long term pain. 
This is primarily because the activation of KORs leads to a decreased release of dopamine in the 
stress pathway of the brain (Sigpa, Lintas, & Diana, 2008). The KORs are the link between the 
psychological and physiological effects of opioids, and the KOR system is thought to be heavily 
involved in reward responses associated with opioid addiction (Cahill et al., 2014). 
While there are different types of opioid receptors, there are also different types of 
molecules that bind to the receptors. Aside from being classified as either endogenous or 
exogenous, opioid ligands can be separated into agonists and antagonists. According to the 
McGraw-Hill Dictionary of Scientific and Technical Terms, an agonist is a molecule that binds 
to a receptor and activates it, producing a response. All the molecules discussed above are 
agonists, and the response they produce is pain relief by inhibiting the pain pathway or stress 
elevation by activating the stress pathway. Antagonists, on the other hand, work to decrease the 
response of the receptors. When an antagonist binds to a receptor, it does not activate the 
receptor and does not create any response. In this case, antagonists cause pain to hurt more, but 
they decrease stress felt.  
Despite their different roles in the body, agonists and antagonists do have one thing in 
common: they can both be used to treat opioid addictions. Agonists are used to avoid opioid 
withdrawal symptoms. Certain agonistic drugs can produce effects similar to those of heroin, 
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without producing the euphoric high. Antagonists are used to block heroin from reaching the 
MOR or KOR. With an antagonist in the body, heroin is rendered useless.  
 Because they differ in structure and properties, both agonists and antagonists have 
distinct advantages and disadvantages as addiction treatments. Therefore, it is now widely 
believed that an addiction treatment which utilizes both agonistic and antagonistic properties 
provides the most efficient addiction recovery process. 
Discussion 
Agonists can produce a wide variety of effects. The pain relief caused by morphine is 
seemingly mild compared to the euphoric highs that heroin is capable of. This range of effects is 
due to the many different structures that agonists have. The structure of an agonist dictates how 
quickly it will enter the brain, how tightly it will bind to the MOR, and ultimately what responses 
it will produce in the body. 
Heroin and morphine are both common agonists, and each one produces a specific 
response. In this example, the key is the fact that heroin is metabolized before it enters the brain, 
while morphine is not. When heroin enters the body it is broken down into 6-monoacetyl-
morphine (6-MAM), in a process known as deacetylation. The 6-MAM is then further 
metabolized into morphine at a later time (Seleman et al., 2014).  
After metabolism, the 6-MAM is able to enter the brain through a P-glycoprotein (P-gp), 
which is regulated by a selective PSC833 inhibitor that is endogenous to the brain (Seleman et 
al., 2014). Opiate drugs like morphine that do not need to be metabolized go directly to the 
glycoprotein after injection. While the PSC833 inhibitor increases the passage of agonists like 
morphine into the brain, it does not have any effect on the transport of 6-MAM. Therefore, 
morphine can only travel efficiently when the P-gp is inhibited by the PSC833. On the other 
hand, 6-MAM is always able to enter the brain, as shown in the graph below (Seleman et al., 
2014). This helps explain why heroin is much more potent, producing more intense highs at 




Figure 1. Effects of P-gp inhibition by the PSC833 on the transport of molecules. The black bars show the amount of 
PSC833 activity that is needed to transport a certain amount of a molecules, shown by the white bars, into the brain. The saline 
shown is used as a control group (Seleman et al., 2014). 
After agonists pass through the brain, they bind to the MOR. In the receptor, they form 
very stable bonds with D147 and H297 amino acid sites (Cong et al., 2015). The importance of 
these bonds has led the H297 site to be referred to as the “opioid anchor.” (Cong et al., 2015). 
The strong hydrogen bond interactions formed at the H297 and D147 sites are able break 
interactions between the R165 and T279 sites. The dissolution of these bonds changes the shape 
of the receptor, moving the transmembrane 6 (TM6) protein subunit, which contains the T279 
site, closer to the transmembrane 3 (TM3) subunit and the R165 site. This shape change, as seen 
in the figure below, makes the MOR temporarily active (Cong et al., 2015).  
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Figure 2. Agonist binding to a MOR. The orange and purple dots denote the H297 and D147 amino acid sites 
respectively, and the red dots show the T279 (left) and R165 (right) sites. The dotted outline shows the position of the TM6 
before agonist binding (Cong et al., 2015). 
While all agonistic binding results in a change of shape in the MOR, the specific number 
and types of bonds formed between the D147 and H297 sites vary, depending on the structure of 
the agonist (Cong et al., 2015). The figure below shows the difference between morphine and 
hydromorphone (HMP), another opioid agonist, in the way that they bind to the receptor. 
Morphine uses a direct hydrogen bond at the H297 site, while HMP uses many water-mediated 
hydrogen bonds. The direct bond that morphine uses is stronger; it causes a more pronounced 
change in the shape of the MOR and results in a larger response (Cong et al., 2015). 
Figure 3. Differences in MOR binding between morphine (A) and HMP (B). The ligand is the orange colored molecule. 
Interactions with the H297 site are shown by green dotted lines. Interactions with the D147 site are shown by purple dotted lines 
(Cong et al., 2015). 
When an agonist binds to a mu opioid receptor located on a GABAergic neuron in the 
ventral tegmental area (VTA), the receptor’s change in shape activates a G-protein pathway that 
halts the production of the GABA neurotransmitter (Chartoff et al., 2014). As seen in the figure 
below, the binding of an agonist causes a G-protein to shut down calcium ion channels that allow 
Ca2+ to enter the neuron and open potassium channels that pump K+ out of the neuron. The G-
protein also deactivates the adenylate cyclase enzyme, which is required to produce cyclic 
adenosine monophosphate (cAMP). When cAMP concentration is decreased, Ih cation currents 
in the neuron are deactivated. These changes cause the neuron to become more negative, making 




Figure 4. The effect of MOR agonists on GABAerigc neuron and dopaminergic neuron interactions. The diagram on 
the left shows the normal interactions in the VTA. The red GABAergic neuron releases GABA (red dots) that inhibits the blue 
dopaminergic neuron. The diagram on the right shows the presence of MOR agonists, in this case, morphine is represented by the 
yellow ovals. Less GABA is synthesized, allowing more dopamine (blue triangles) to be released. The green neuron represents 
Glutamatergic neurons that are also present in the VTA. (Chartoff et al., 2014). 
Agonist structure plays a big role even after the opioid has bonded to the MOR. (Seleman 
et al., 2014). Agonists that form strong bonds, such as morphine, release more dopamine for a 
longer period of time, as compared to weaker agonists like HMP. Also, the PSC833 inhibitor at 
the entrance to the brain has been shown in some cases to have the ability to change the intensity 
of the response that an agonist like morphine produces (Seleman et al., 2014). 
Despite structural differences, all opioid agonists create a lack of inhibitory GABA 
molecules in the VTA. This stops the inhibition of dopaminergic neurons and allows the release 
of dopamine (Haile, Kosten & Kosten, 2008). The resulting flood of released dopamine is the 
cause of the characteristic opioid high. The dopamine primarily affects the frontal regions of the 
brain, specifically the nucleus accumbens and the prefrontal cortex. Unsurprisingly, these regions 
are known to have an important role in the addiction process (Haile, Kosten & Kosten, 2008). 
While opioid receptor agonists are known for causing these highs that lead to addictions, 
they can also be used to help recovering addicts. Agonists are often used to relieve withdrawal 
symptoms. They can stop the feelings of sickness or dizziness without causing the dangerously 
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addictive highs. Of all the agonists used for opiate addiction treatment, methadone has proven to 
be the most successful. 
Methadone maintenance treatment (MMT) was first approved in the 1960s and soon 
became one of the most widespread and effective methods for treating opiate addiction (Bart, 
2012). Methadone, pictured below, works by stabilizing the mu opioid receptor post-heroin use. 
When methadone binds to the MOR, it activates the G-protein a little differently. Methadone 
causes the G-protein to activate protein transcription factors that changes which proteins are 
being created in the neuron. Using this process, methadone can slowly reverse the effects of 
heroin abuse (Toskulkao et al., 2010). This effect is illustrated by the fact that methadone can 
decrease the tolerance to heroin that the body has developed. 
                                               
Figure 5. Structure of methadone 
When addicts keep using heroin, the body acknowledges the increased concentrations of 
opioid ligand and responds by producing more mu opioid receptors (Toskulkao et al., 2010). 
This increase in receptor number makes the addict more tolerant to heroin, since they need a 
larger dose to fill all the MORs. Studies have shown that methadone regulates the production of 
MORs by affecting the genes that code for the receptors. In patients receiving methadone 
treatments, the messenger ribonucleic acid (mRNA) molecules that provide the code for the 
production of MORs are decreased by about 36.6% as compared to pre-treatment levels. This 
means that methadone actually decreases the number of MORs in the body, as seen in the figure 
below. Methadone restores the receptor concentration to normal levels and decreases an addict’s 
tolerance to heroin (Toskulkao et al., 2010). 
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Figure 6. The effects of methadone on MOR concentration. The graph plots the amount of the antagonist naloxone 
introduced to the body versus the amount of naloxone that binds to a MOR. Since methadone decreases the amount of MORs 
present, less naloxone is able to bind (Toskulkao et al., 2010). 
Methadone can have many sociological benefits as well. The treatment allows patients to 
resume a fairly normal life. They are able to live at home and go to work; the only catch is that 
patients have to stop into a clinic every day to be tested for heroin use and to receive the next 
dose of methadone (Goldstein, 2001). Another disadvantage to methadone is that patients are 
usually unable to stop taking the medication. Patients become dependent on methadone, and 
ceasing to use it brings about the return of heroin withdrawal symptoms, which often leads to a 
heroin relapse. (Goldstein, 2001). Due to this dependency, patients on methadone are often still 
regarded as addicts by society. 
 A survey of 315 patients showed that 80% of addicts currently using methadone believe 
that after a certain period, patients should try to get off methadone (Stancliff et al., 2002). 36% 
believe that other addicts look down on those receiving methadone treatment, and 58% are 
unwilling to talk to friends or family members about their treatments. These negative 
connotations that surround methadone can lead to isolation of the patient; some methadone 
patients even find themselves being denied certain medical procedures such as kidney transplants 
(Stancliff et al., 2002).  
Overall, 60% of patients will remain in a one year methadone program (Bart, 2012). 
However, the majority of these patients will then remain on methadone for the rest of their lives. 
Weckerly 9 
 
Unfortunately, about 15% of patients being treated with methadone will be using opiates 
simultaneously and are the most likely to have a relapse (Bart, 2012).  
In comparison to agonists, antagonists have vastly different properties, but have also had 
a lot of success in the treatment field. Antagonists bind to MORs in a way that blocks the 
response that heroin or other opiates produce. Antagonists shut down the opioid’s signaling 
pathway and stop the body from responding to opioids agonists like heroin. 
 Antagonists bind to the same H297 and D147 sites as agonists do; however, antagonists 
use a pattern of hydrogen bonds at the H297 site that is much weaker than the interactions used 
to anchor agonists (Cong et al., 2015). As a result of these weaker interactions, antagonists are 
not able to break the hydrogen bonds that are holding the T279 and R165 sites together. 
Therefore, these hydrogen bonds between the T279 and R165 sites stabilize the structure of the 
MOR in an inactive position, as seen in the figure below (Cong et al., 2015).  
 
Figure 7. Antagonistic binding to MORs. The dotted red line shows hydrogen bonding between the T279 site and the 
R165 site that keeps the receptor in an inactive position (Cong et al., 2015). 
Since antagonists do not change the shape of the MOR, G-proteins are not activated. As 
seen in the figure below (Chartoff et al., 2014). cAMP production continues, potassium pumps 
stay inactive, calcium channels remain open, and Ih cation currents continue to flow. The interior 
of the GABAergic neuron remains positive, allowing action potentials to release GABA that then 






Figure 8. Antagonistic interactions in the VTA. Antagonists block the effects of opioid agonists, inducing withdrawal. 
Calcium channels and cation currents continue to work in GABAergic neurons (shown in red). Therefore, large amounts of 
GABA (red dots) are released, which significantly decreases dopamine (blue triangles not shown) production by the blue 
dopaminergic neuron. The neuron in green represents glutamatergic neurons that also regulate dopamine release in the VTA 
(Chartoff et al., 2014). 
The main antagonist used for opioid addiction treatment is naltrexone, pictured below. 
When naltrexone is present in the body, it uses the process described above to keep the interior 
of the GABAergic neurons positively charged. However, when agonists like heroin are 
introduced, they create a response that leads to a negatively charged interior. Therefore when 
heroin is used in the presence of naltrexone, the effects of naltrexone and heroin negate each 
other, rendering heroin useless. When a patient is taking naltrexone, they can inject all the heroin 





Figure 9. Structure of naltrexone. 
While naltrexone can block the effects of opiate agonists, it cannot stop the withdrawal 
symptoms felt by the addict during the treatment (Van Bockstaele et al., 2008). However, the 
timing of naltrexone administration can cause a slight decrease in the intensity of withdrawal 
symptoms. Naltrexone treatments can be implemented when an addict has already stopped using 
opiates, and therefore is already in the withdrawal period. Naltrexone can also be taken while 
opiates are still in the addict’s system, in which case naltrexone’s antagonistic properties negate 
the effects of all opiates and induce withdrawal in an addict (Van Bockstaele et al., 2008). 
When an individual is going through opiate withdrawal, norepinephrine begins to flood 
the brain, causing withdrawal symptoms such as shivering, shaking and diarrhea (Van 
Bockstaele et al., 2008). Though naltrexone cannot stop this spike in norepinephrine levels, using 
naltrexone to induce withdrawal can decrease the magnitude of norepinephrine released and 




Figure 10. Effects of naltrexone on the amount of norepinephrine released in morphine addicted rats. The open dots 
show the effects of naltrexone (added at the arrow) when the addict is already going through withdrawal.  The closed dots show 
the norepinephrine released when withdrawal is induced by naltrexone added to the rats’ drinking water. The blank line shows 
the control group. (Van Bockstaele et al., 2008).   
Naltrexone cannot stop withdrawal symptoms the way that methadone can. The principle 
behind naltrexone is that it conditions addicts to stop using heroin (Kunøe et al., 2010). Addicts 
on naltrexone continue to crave heroin. However, when this craving leads to heroin use, the 
opiate produces no effect. After enough times of taking heroin with no euphoria, the theory is 
that addicts will stop associating heroin with highs, which will eventually cause them to stop 
craving heroin or seeking it to mitigate their withdrawal symptoms (Kunøe et al., 2010).  
However, heroin cravings often get bad enough that they cause patients to stop using 
naltrexone. Since patients know that giving up naltrexone will produce the high that they desire, 
it is very easy for them to stop using the antagonist in favor of heroin. Although the number of 
patients who quit naltrexone is not easily determined, a strong indication of this number is seen 
by looking at patients who “challenge” naltrexone. 
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As the graph below shows, many patients still try to use heroin while on naltrexone 
(Kunøe et al., 2010). The patients are said to be “challenging” naltrexone; they are craving 
heroin and are curious to see if naltrexone can really stop heroin’s highs. This challenging 
behavior ideally should decrease the longer the patient is on naltrexone, eventually resulting in 
no heroin use. However, many patients find that their willpower weakens over time and will 
challenge naltrexone more toward the end of the treatment (Kunøe et al., 2010).  
           
Figure 11. Number of naltrexone patients who used heroin or other opiates over a treatment period of 180 days. (Kunøe 
et al., 2010). 
Of the 60 patients used in this study, about 56% challenged naltrexone over the six month 
period, while a quarter of the patients used opioids repeatedly while on naltrexone (Kunøe et al., 
2010). Historically, this does not bode well for the probability of these patients remaining in 
treatment. While these studies forced the use of naltrexone over the entire six month period, in 
real life situations it is much harder to find the motivation to stay on naltrexone (Kunøe et al., 
2010).  
Another downfall to naltrexone is the fact that it may not block all doses of heroin 
(Kunøe et al., 2010). When patients challenge naltrexone, it leads them to try higher and higher 
doses of heroin in hopes of getting a response. These larger doses increase the chances of a 
heroin molecule binding to a MOR instead of a naltrexone molecule binding to a MOR. 61% of 
the patients who used opiates while on naltrexone reported that they felt no high, but 12% of the 
opiate users reported that they felt a full high at least some of the times they used opiates (Kunøe 
et al., 2010). Unfortunately, these highs only reinforce the challenging behavior and eventually 
convince patients to stop taking naltrexone. 
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While methadone and naltrexone both have their strengths, they also have weaknesses 
that can lead to relapsing. To fill in the gaps that both agonist treatments and antagonist 
treatments have, a treatment has been developed that combines the two methods. Buprenorphine 
(BUP), pictured below, acts as both an agonist at mu opioid receptors and a partial antagonist at 
kappa opioid receptors (Haile, Kosten & Kosten, 2008). It is just like methadone in the way it 
gives relief from withdrawal symptoms and facilitates the return of normal physiological 
functioning, but BUP also blocks negative effects, such as stress, caused by further opioid use 
(Bart, 2012). 
 
Figure 12. Structure of buprenorphine 
The key to BUP’s success is the fact that it blocks the kappa opioid receptor rather than 
blocking the mu opioid receptor (Spiga, Lintas & Diana, 2008). The antagonism of the KOR 
halts the stress response that often accompanies withdrawal (Knoll et al., 2007). This decreased 
stress response is thought to help retain many brain functions, such as memory storage and 
decision making, as well as decreasing stress (Knoll et al., 2007). This can ultimately help speed 
up recovery and lessen withdrawal’s side effects (Spiga, Lintas & Diana, 2008). 
Studies have tested the effects of KOR agonists in order to understand the KOR’s role in 
rats’ fear response (Knoll et al., 2007). A stressful situation leads to the activation of a cAMP 
dependent transcription factor called the cAMP-response element binding protein (CREB). The 
CREB then induces the synthesis of dynorphins by initiation the transcription of certain genes. 
The excess agonistic dynorphins then flood the nucleus accumbens where they bind to the KORs 
(Knoll et al., 2007). 
 The dynorphins, kappa opioid receptors agonists, bind in a way very similar to MOR 
binding. The KOR is coupled with a G-protein in a dopaminergic neuron (McLaughlin et al., 
2004). Agonist binding causes a change in the KOR’s structure that activates the G-protein.  The 
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G-protein in turn activates a G-protein dependent kinase. The kinase is then responsible for the 
phosphorylation of proteins that help create an action potential in the dopaminergic neuron and 
lead to the release of dopamine, thus creating a stress response (McLaughlin et al., 2004). 
 Just like antagonistic MOR binding, when an antagonist like buprenorphine binds to the 
KOR, the G-protein is not activated since there is no change in the shape of the receptor. The 
halted pathway stops the release of dopamine and inhibits the stress response. This lowering of 
stress is part of the reason that KOR antagonists like buprenorphine are so effective, considering 
that stress is one of the major factors that can lead to drug seeking and ultimately a relapse 
(Sedki et al., 2014). 
 One study showed the effects of KOR antagonists on drug seeking behavior in rats (Sedki 
et al., 2014). Over a period of ten days, the rats were conditioned that pressing an “active” lever 
would dispense heroin, while an “inactive” lever would not. The rats then went through food-
deprivation in order to expose them to stress. As seen in the charts below, the rats that received 
the KOR antagonist norbinaltorphimine (norBNI) used the active lever less while in the food-
deprivation period. This supports the idea that the norBNI decreased the stress response in the 
rats, therefore reducing that rats’ tendency to use heroin (Sedki et al., 2014). 
 
Figure 13. Graph showing the number of times rats pressed the active lever to dispense heroin. Baseline shows the 
number of times each group of rats pressed the lever before any norBNI was added. The “sated” column measures the number of 
times the lever was pushed when the rats had received norBNI, but were not under stress. The “food deprived” column shows the 
number of times the lever was pushed when the rats received norBNI and were under stress. This last column shows how KOR 
antagonism decreases the stress response. (Sedki et al., 2014). 
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 However, due to variations in structure and location, only KOR antagonism lessens the 
stress response (Sedki et al., 2014). When the same experiment was repeated using naltrexone, 
an effective MOR antagonist, the number of times the active lever was pushed actually 
increased, as shown below. This indicates that naltrexone can actually increase the stress 
response, which is most likely another factor that contributes to the high relapse rates among 
naltrexone patients (Sedki et al., 2014). 
 
Figure 14. Effects of naltrexone on the stress response. The figure graphs the number of times the active lever was 
pushed under different conditions: baseline (no naltrexone, no stress), sated (naltrexone, no stress), and food deprived (naltrexone 
and stress) (Sedki et al., 2014). 
Buprenorphine, as a partial KOR antagonist, displays these same stress reducing effects. 
This property can not only decreases the chance of a relapse, but it can also preserve certain 
brain functions as opposed to other opioid treatments. When subjected to memory and brain 
function testing, BUP patients score almost identically to the non-addict control population, 
while methadone patients received a large differences in scores (Spiga, Lintas & Diana, 2008).  
For example, as seen in the charts below, methadone patients have less decision making 
abilities. They made more disadvantageous choices, shown in white, and did not make as many 
advantageous ones, shown in blue, when completing the Iowa Gambling Task (IGT). It was also 
shown by the matching-to-sample test (MTS) that methadone patients need more trials before 




Figures 15a and 15b. 13a shows the results of the IGT test when taken by a control group, methadone patients, and 
BUP patients. The blue bars depict the number of advantageous cards picked, showing good, stable decisions. The white bars 
show disadvantageous cards picked, denoting bad or high risk decisions. 13b shows the number of trials performed until 
members of each group could properly complete a matching-to-sample test (Spiga, Lintas & Diana, 2008). 
Due to its more effective treatment, BUP is quickly becoming the most widely used 
opioid addiction treatment method. Aside from its pharmacological advantages, BUP has many 
social benefits that attract recovering addicts (Gryczynski et al., 2013). BUP has less regulations 
when it comes to using it; this can reduce the stress on patients, as they are able to meet in a 
more comfortable office setting and pick up prescriptions from a pharmacy, receiving their 
treatments sooner and more discretely. Also, doses of BUP are stronger and therefore do not 
need to be taken as frequently, which causes significantly less interruptions in the patient’s life 
(Gryczynski et al., 2013).   
BUP is preferred over naltrexone because it alleviates withdrawal symptoms as well as 
decreasing the stress response. These pharmacological effects, plus BUP’s social benefits, cause 
patients to prefer BUP over methadone as well. A recent study surveyed patients to ask them 
why they chose a BUP treatment over methadone. Patients were given a series of options 
pertaining to BUP and methadone and were asked which ones were the most influential in their 
decision. As the table below shows, many patients turned to BUP because they believed it to be 




Figure 16. Table showing the importance of different factors that led patients to choose BUP treatment over methadone 
(Gryczynski et al., 2013). 
BUP’s and methadone’s different pharmacological effects can come down to the patient’s 
individual genetics and biochemistry and, of course, the drug’s molecular structure and 
properties. For example, methadone is broken down by a particular liver enzyme used in the 
metabolism of drugs, cytochrome P3A4 (CYP3A4). BUP, on the other hand, uses a different 
metabolic enzyme, cytochrome P2D6 (CYP2D6) (Haile, Kosten & Kosten, 2008). 
The need for different enzymes results from structural differences between buprenorphine 
and methadone (Coller et al., 2012).  While both of the exogenous drugs require an enzyme to 
remove a methyl group, a process called demethylation, the specific location of the methyl group 
determines the specific enzyme that will catalyze the reaction. Buprenorphine, pictured below, 
has a methyl group attached to an oxygen atom. Methadone, on the other hand, has two methyl 
groups attached to a nitrogen atom. The CYP3A4 enzyme only facilitates N-demethylation, the 
removal of methyl groups from nitrogen atoms. The CYP2D6 enzyme catalyzes O-methylation 
by taking a methyl group off of an oxygen atom (Coller et al., 2012).  
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Figure 17a and 17b. Structure of buprenorphine (left) and methadone (right). Methyl groups are circled in red. 
In many Caucasian populations, it is common to lack the gene that codes for the CYP2D6 
needed to break down BUP (Haile, Kosten & Kosten, 2008). People who lack this gene are 
satisfied with methadone treatment, but often cannot metabolize normal doses of BUP due to the 
specificity of these enzymes (Haile, Kosten & Kosten, 2008). 
This enzyme specificity can be seen in the metabolism of tramadol, an opiate painkiller 
similar to oxycodone (Coller et al., 2012). Tramadol is broken down into O-desmethyl-tramadol 
(M1) by CYP2D6 and N-desmethyltramadol (M2) by CYP3A4. As seen in the chart below, 
methadone patients that use the CYP3A4 enzyme produce higher levels of M2, while BUP 
patients that use CYP2D6 produced higher levels of M1. 
Figure 18. Ratios of tramadol metabolites. Numbers show the percent of the original tramadol dose that was found in 
urine samples as each metabolite. MMT stands for patients on methadone maintenance treatment, while BMT denotes patients on 
buprenorphine maintenance treatment (Coller et al., 2012).  
Conclusion 
Dozens of opioids have been discovered since the first ancient use of opium from poppy 
plants. Each opioid has a unique structure and properties. For example, agonists activate specific 
receptors in the central nervous system in order to create a response. In this case, agonists like 
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heroin produce a high. Antagonists, on the other hand, block receptors and decrease the euphoric 
response. 
The receptors utilized by opioids are found throughout the nervous system, and they 
possess various structures and functions as well. The mu opioid receptors (MORs) are primarily 
involved with addiction; they are responsible for heroin’s characteristic highs. The kappa opioid 
receptors (KORs) help regulate the stress response and cognition changes that often accompany 
chronic pain. 
While the different types of receptors can interact with the different opioids to create 
highs and lead to addiction, opioids and their receptors can also be used as addiction treatments 
for recovering addicts. By utilizing their respective properties, both agonists and antagonists can 
be used to treat opiate addiction. However, each type of treatment has various drawbacks. 
Therefore, the most effective opiate addiction treatment is a drug that combines agonistic 
properties with antagonistic ones. 
Agonists work by changing the shape of the MOR into an active position which activates 
a G-protein system that inhibits GABAergic neurons and causes an increase in the release of 
dopamine. Though this process is essentially the same for all agonistic molecules, differences in 
agonist structure create slightly different responses. For example, different agonists may be able 
to enter through into the brain easier than others. The structure of agonists also determines how 
tightly the molecule binds to the MOR, which affects the intensity of the response. 
Methadone is the most popular agonist used for opiate addiction treatment. Methadone 
prevents the symptoms of heroin withdrawal and stabilizes the body’s natural functioning. For 
example, methadone can decrease tolerance to heroin by decreasing the number of MORs 
present in the body. Despite methadone’s pharmacological effects, addicts find that the treatment 
is too disruptive to everyday life, and they do not like the thought of being dependent on another 
medication (Stancliff et al., 2002). 
Antagonists use a different approach to addiction treatment. Antagonists bind to the 
MOR and change it to an inactive position. The receptor’s inactive position stops the G-protein 
pathway. This allows GABAergic neurons to decrease the amount of dopamine released, which 
negates the euphoria that agonists like heroin produce.  
The antagonist commonly used for opiate treatment is naltrexone. Naltrexone works at 
MORs to negate all the effects of heroin use. While naltrexone can induce withdrawal, it cannot 
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stop the symptoms felt during the process. However, due to various interactions, using 
naltrexone at specific stages of withdrawal can slightly reduce the symptoms. Though it can have 
a small effect on withdrawal symptoms, naltrexone’s main function is to condition addicts so 
they no longer associate heroin with a high. However, patients on naltrexone often “challenge” 
the drug by trying opiates while on treatments, increasing the probability that they will 
eventually give up naltrexone in favor of heroin (Kunøe et al., 2010). 
To avoid the disadvantages that methadone and naltrexone produce, scientists have 
developed buprenorphine (BUP). Buprenorphine is found to be much more effective because it 
acts as a MOR agonist and a KOR antagonist. When BUP blocks KORs, it can decrease the 
stress that accompanies withdrawal and better preserve certain brain functioning that makes 
treatment much more effective. Also, BUP is less disruptive to a patient’s life because it has less 
frequent doses and less regulations. 
Buprenorphine combines the agonistic effects of methadone with the antagonistic effects 
of naltrexone. Therefore, it can provide relief from withdrawal symptoms, while using 
antagonism at KORs, which is much more effective than MOR antagonism. The simple fact that 
BUP can interact with KORs instead of MORs is the key that makes the BUP treatment method a 
lot more successful than methadone or naltrexone. This once again supports the idea that small 
structural differences between opioids have a large effect on the response produced. BUP is the 
most effective treatment since its structure allows it to work where methadone and naltrexone 
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